Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$1.00 +3.0%	$0.83	$0.51 ▼ $1.63	$55.56M	-0.27	55,422 shs	30,069 shs
LTRN Lantern Pharma	$3.19 +1.6%	$3.42	$2.55 ▼ $6.12	$34.39M	1.55	61,840 shs	40,336 shs
NEUP Neuphoria Therapeutics	$7.00 +2.9%	$5.99	$2.12 ▼ $12.55	$13.16M	0.46	24,029 shs	49,447 shs
NRXP NRx Pharmaceuticals	$3.42 -2.3%	$2.67	$1.10 ▼ $6.01	$59.13M	1.54	417,602 shs	258,499 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-2.91%	+27.91%	+81.82%	-34.21%
LTRN Lantern Pharma	0.00%	+0.31%	+5.98%	-9.89%	-31.69%
NEUP Neuphoria Therapeutics	0.00%	+2.94%	+6.87%	+21.53%	+699,999,900.00%
NRXP NRx Pharmaceuticals	0.00%	+4.91%	+30.53%	+66.83%	+40.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTB Connect Biopharma	3.7946 of 5 stars	3.5	5.0	3.8	2.5	0.6
LTRN Lantern Pharma	2.2671 of 5 stars	3.5	2.0	2.7	0.8	0.6
NEUP Neuphoria Therapeutics	1.8696 of 5 stars	3.5	0.0	2.6	0.0	0.6
NRXP NRx Pharmaceuticals	2.0188 of 5 stars	3.6	1.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	3.00	Buy	$7.00	600.00% Upside
LTRN Lantern Pharma	3.00	Buy	$25.00	683.70% Upside
NEUP Neuphoria Therapeutics	3.00	Buy	$21.00	200.00% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	733.33% Upside

Current Analyst Ratings Breakdown

Latest NEUP, NRXP, LTRN, and CNTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
4/2/2025	LTRN Lantern Pharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
4/2/2025	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
3/31/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/31/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$26.03M	2.13	N/A	N/A	$1.67 per share	0.60
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$1.96 per share	N/A
NEUP Neuphoria Therapeutics	$10K	1,316.00	N/A	N/A	$15.85 per share	0.44
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
LTRN Lantern Pharma	-$20.78M	-$1.84	N/A	N/A	N/A	N/A	-83.26%	-70.65%	8/6/2025 (Estimated)
NEUP Neuphoria Therapeutics	-$15.49M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	-$25.13M	-$2.01	N/A	N/A	N/A	N/A	N/A	-355.00%	8/13/2025 (Estimated)

Latest NEUP, NRXP, LTRN, and CNTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q3 2025	NEUP Neuphoria Therapeutics	-$0.47	$6.55	+$7.02	$6.55	N/A	$15.00 million
5/15/2025	Q1 2025	CNTB Connect Biopharma	-$0.26	-$0.19	+$0.07	-$0.19	N/A	N/A
5/15/2025	Q1 2025	LTRN Lantern Pharma	-$0.49	-$0.42	+$0.07	-$0.42	N/A	N/A
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	10.25	10.25
LTRN Lantern Pharma	N/A	4.86	4.86
NEUP Neuphoria Therapeutics	N/A	11.01	11.01
NRXP NRx Pharmaceuticals	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
LTRN Lantern Pharma	28.62%
NEUP Neuphoria Therapeutics	15.90%
NRXP NRx Pharmaceuticals	4.27%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
LTRN Lantern Pharma	7.31%
NEUP Neuphoria Therapeutics	0.69%
NRXP NRx Pharmaceuticals	19.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	110	55.56 million	43.00 million	Optionable
LTRN Lantern Pharma	20	10.78 million	10.00 million	Optionable
NEUP Neuphoria Therapeutics	N/A	1.88 million	1.87 million	N/A
NRXP NRx Pharmaceuticals	2	17.29 million	14.00 million	Optionable

NEUP, NRXP, LTRN, and CNTB Headlines

Recent News About These Companies

NRx Pharmaceuticals, Inc. (NRXP) - Yahoo Finance

June 27 at 11:25 PM | finance.yahoo.com

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional ...

June 27 at 6:24 PM | nasdaq.com

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic

June 27 at 6:24 PM | finance.yahoo.com

NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic

June 26, 2025 | financial-news.co.uk

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

June 26, 2025 | prnewswire.com

NRX Pharmaceuticals Inc News (NRXP) - Investing.com

June 24, 2025 | investing.com

IBN Initiates Coverage of NRx Pharmaceuticals Inc.

June 24, 2025 | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

June 23, 2025 | prnewswire.com

NRx Pharmaceuticals (NASDAQ:NRXP) Receives "Buy" Rating from D. Boral Capital

June 20, 2025 | marketbeat.com

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

June 17, 2025 | finance.yahoo.com

NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

June 16, 2025 | financial-news.co.uk

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. ...

June 16, 2025 | gurufocus.com

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners

June 16, 2025 | prnewswire.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of "Buy" from Brokerages

June 16, 2025 | marketbeat.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 12, 2025 | prnewswire.com

NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

June 6, 2025 | financial-news.co.uk

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

June 6, 2025 | finance.yahoo.com

NRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at D. Boral Capital

June 6, 2025 | marketbeat.com

NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine

June 5, 2025 | financial-news.co.uk

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine

June 5, 2025 | finance.yahoo.com

New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms

June 5, 2025 | usatoday.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP, NRXP, LTRN, and CNTB Company Descriptions

Connect Biopharma NASDAQ:CNTB

$1.00 +0.03 (+3.04%)

Closing price 06/27/2025 03:46 PM Eastern

Extended Trading

$1.10 +0.10 (+10.00%)

As of 04:00 AM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Lantern Pharma NASDAQ:LTRN

$3.19 +0.05 (+1.59%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.00 +0.81 (+25.39%)

As of 04:00 AM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Neuphoria Therapeutics NASDAQ:NEUP

$7.00 +0.20 (+2.94%)

As of 06/27/2025 04:00 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

NRx Pharmaceuticals NASDAQ:NRXP

$3.42 -0.08 (-2.29%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.43 +0.01 (+0.29%)

As of 05:18 AM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time